JP2021510715A - 白血病治療のための併用療法 - Google Patents

白血病治療のための併用療法 Download PDF

Info

Publication number
JP2021510715A
JP2021510715A JP2020539240A JP2020539240A JP2021510715A JP 2021510715 A JP2021510715 A JP 2021510715A JP 2020539240 A JP2020539240 A JP 2020539240A JP 2020539240 A JP2020539240 A JP 2020539240A JP 2021510715 A JP2021510715 A JP 2021510715A
Authority
JP
Japan
Prior art keywords
iron
leukemia
artemisinin
arsenic trioxide
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020539240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021510715A5 (https=
Inventor
マシューズ、ヴィクラム
クリシュナ、サンジーヴ
シドニー オーガスティン、ヨランダ
シドニー オーガスティン、ヨランダ
Original Assignee
セントジョージズ ホスピタル メディカル スクール
セントジョージズ ホスピタル メディカル スクール
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セントジョージズ ホスピタル メディカル スクール, セントジョージズ ホスピタル メディカル スクール filed Critical セントジョージズ ホスピタル メディカル スクール
Publication of JP2021510715A publication Critical patent/JP2021510715A/ja
Publication of JP2021510715A5 publication Critical patent/JP2021510715A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020539240A 2018-01-17 2019-01-17 白血病治療のための併用療法 Pending JP2021510715A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1800736.9A GB201800736D0 (en) 2018-01-17 2018-01-17 Combination therapy for treatment of leukemia
GB1800736.9 2018-01-17
PCT/GB2019/050124 WO2019141988A1 (en) 2018-01-17 2019-01-17 Combination therapy for treatment of leukemia

Publications (2)

Publication Number Publication Date
JP2021510715A true JP2021510715A (ja) 2021-04-30
JP2021510715A5 JP2021510715A5 (https=) 2022-01-24

Family

ID=61256143

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020539240A Pending JP2021510715A (ja) 2018-01-17 2019-01-17 白血病治療のための併用療法

Country Status (6)

Country Link
US (1) US11400112B2 (https=)
EP (1) EP3740215A1 (https=)
JP (1) JP2021510715A (https=)
CN (1) CN111818930A (https=)
GB (1) GB201800736D0 (https=)
WO (1) WO2019141988A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220226372A1 (en) * 2019-05-21 2022-07-21 Medsenic Use of metal ions to potentiate the therapeutic effects of arsenic
EP3868372A1 (en) * 2020-02-19 2021-08-25 JLP Health GmbH A pharmaceutical combination of an artemisinin compound and a heme synthesis modulator for treating cancer
US11583552B2 (en) 2021-02-17 2023-02-21 Manoj Maniar Pharmaceutical formulation of arsenic trioxide
CN116687965A (zh) * 2023-05-05 2023-09-05 杭州市西溪医院 一种三氧化二砷-青蒿琥酯抗肿瘤组合物、双载药纳米脂质体及其制备方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04273819A (ja) * 1991-02-28 1992-09-30 Takeda Chem Ind Ltd 血圧上昇剤
JP2001522799A (ja) * 1997-11-10 2001-11-20 メモリアル スローン−ケタリング キャンサー センター 三酸化ヒ素製剤の製造方法および三酸化ヒ素またはメラルソプロールを使用する癌の治療方法
JP2005529938A (ja) * 2002-06-06 2005-10-06 ユニバーシティ オブ ワシントン 癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法
JP2008201765A (ja) * 2007-01-26 2008-09-04 Jichi Medical Univ 腫瘍治療における三酸化二ヒ素の副作用低減剤及び解毒剤
JP2016500117A (ja) * 2012-11-29 2016-01-07 昆明制薬集団股▲分▼有限公司 アルテメーテル含有医薬組成物、製剤およびその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1044559C (zh) 1995-08-23 1999-08-11 哈尔滨医科大学附属第一医院 抗白血病、肝癌、淋巴瘤注射液
CN102614168A (zh) * 2011-01-31 2012-08-01 上海交通大学医学院附属瑞金医院 一种青蒿素衍生物及其药用盐的应用
CN103202835B (zh) 2012-01-16 2015-05-13 上海交通大学医学院附属瑞金医院 青蒿素衍生物及其药用盐用于制备治疗急性白血病的药物
CN103202836B (zh) 2012-01-16 2015-05-13 上海交通大学医学院附属瑞金医院 青蒿素衍生物及其药用盐用于制备治疗急性髓细胞性白血病的药物
CN103202837B (zh) 2012-01-16 2015-05-13 上海交通大学医学院附属瑞金医院 青蒿素衍生物及其药用盐用于治疗制备白血病的药物
US9801851B2 (en) 2012-05-23 2017-10-31 St. Jude Children's Research Hospital Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias
CN103845322A (zh) 2012-11-29 2014-06-11 昆明制药集团股份有限公司 蒿甲醚在制备治疗白血病的药物中的用途
CN104739824A (zh) 2013-12-30 2015-07-01 昆山达人生物医药有限公司 双氢青蒿素在制备抑制肿瘤生长药物中的应用
EP3233918A1 (en) * 2014-12-19 2017-10-25 Novartis AG Combination therapies
US9918972B2 (en) 2014-12-23 2018-03-20 The University Of Maryland, Baltimore Treatment of leukemia with artemisinin derivatives and combinations with other antineoplastic agents
US10925963B2 (en) 2015-06-22 2021-02-23 Washington University Combination artemisinin and chemiluminescent photodynamic therapy and uses therefor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04273819A (ja) * 1991-02-28 1992-09-30 Takeda Chem Ind Ltd 血圧上昇剤
JP2001522799A (ja) * 1997-11-10 2001-11-20 メモリアル スローン−ケタリング キャンサー センター 三酸化ヒ素製剤の製造方法および三酸化ヒ素またはメラルソプロールを使用する癌の治療方法
JP2005529938A (ja) * 2002-06-06 2005-10-06 ユニバーシティ オブ ワシントン 癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法
JP2008201765A (ja) * 2007-01-26 2008-09-04 Jichi Medical Univ 腫瘍治療における三酸化二ヒ素の副作用低減剤及び解毒剤
JP2016500117A (ja) * 2012-11-29 2016-01-07 昆明制薬集団股▲分▼有限公司 アルテメーテル含有医薬組成物、製剤およびその使用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Arsenic Trioxide and Artemisinin Act Synergistically to Kill Tumor Cells In Vitro", ANTICANCER AGENTS MED CHEM, vol. 18(15), JPN6022045647, 2018, pages 2178 - 2186, ISSN: 0004910430 *
"Artesunate possesses anti-leukemia properties that can be enhanced by arsenic trioxide", LEUK LYMPHOMA, vol. 55(6), JPN6022045640, 2014, pages 1366 - 72, ISSN: 0005070737 *
"Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron", FREE RADIC BIOL MED, vol. 37(7), JPN6022045641, 2004, pages 998 - 1009, ISSN: 0005070738 *
"Evaluation of artemisinins for the treatment of acute myeloid leukemia Cancer Chemother Pharmacol", CANCER CHEMOTHER PHARMACOL, vol. 77(6), JPN6022045645, 2016, pages 1231 - 43, ISSN: 0005070741 *
"Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin", CANCER LETT, JPN6022045644, 1995, pages 41 - 6, ISSN: 0005070740 *
中瀬 朋夏: "『伝統薬から開発された抗マラリア薬でがんを治す』 漢方がん治療：アルテミシニンの抗がん活性", 日本薬理学雑誌, vol. 143 巻, JPN6022045642, 2014, pages 61 - 64, ISSN: 0005070739 *

Also Published As

Publication number Publication date
GB201800736D0 (en) 2018-02-28
US20200345770A1 (en) 2020-11-05
WO2019141988A1 (en) 2019-07-25
EP3740215A1 (en) 2020-11-25
CN111818930A (zh) 2020-10-23
US11400112B2 (en) 2022-08-02

Similar Documents

Publication Publication Date Title
Gordan et al. Involvement of cytosolic and mitochondrial iron in iron overload cardiomyopathy: an update
JP2021510715A (ja) 白血病治療のための併用療法
Goyal et al. The cardioprotective role of N-acetyl cysteine amide in the prevention of doxorubicin and trastuzumab–mediated cardiac dysfunction
KR20180116298A (ko) 화학요법 유도 심장독성에 대응하기 위한 약제학적 조성물 및 방법
CN108025187A (zh) 靶向nad+以治疗化学疗法和放射疗法引发的认知损害、神经病变和不活动
EP1323423B1 (en) Combined preparation comprising a morpholinyl anthracycline derivative and a topoisomerase II inhibitor
RU2492862C2 (ru) Противоопухолевые средства с бензофенантридиновой структурой и содержащие их препараты
AU2016285597A1 (en) Combination of HDAC inhibitor and anti-PD-L1 antibody for treatment of cancer
JP7510411B2 (ja) 癌療法のための二機能性組成物
EA032345B1 (ru) Способ лечения рака с использованием кофермента q10
JPH08502488A (ja) 前立腺癌および初期神経悪性疾患に対するベンゾキノイドアンサマイシンの殺腫瘍活性
US20240382512A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
EP3532289B1 (en) Polyoxometalate complexes and uses in managing cancer
Shao et al. Biotinylated curcumin as a novel chemosensitizer enhances naphthalimide-induced autophagic cell death in breast cancer cells
CA2992033A1 (en) Fucosidase inhibitors
US20220008451A1 (en) Flavin adenine dinucleotide (fad) for use in the prevention and/or treatment of cancer
US9937261B2 (en) Combination therapy comprising a liposomal prodrug of mitomycin C and radiotherapy
JP2006513223A (ja) ｐ−アミノ安息香酸（ＰＡＢＡ）によるメラニン形成及びメラノーマ転移の阻害
JP7032406B2 (ja) ダクチノマイシン組成物並びに骨髄異形成症候群及び急性骨髄性白血病の治療方法
CZ2004287A3 (cs) Prostředky a způsoby pro léčení rakoviny
US20120156311A1 (en) Combination therapy for cancer comprising a platinum-based antineoplastic agent and a biocompatible electron donor
US8729133B2 (en) Method for treating cancer
WO2021023291A1 (zh) 原黄素在肺癌治疗中的应用
Liu et al. Therapeutic efficacy of NSC606985, a novel camptothecin analog, in a mouse model of acute promyelocytic leukemia
KR20200021895A (ko) 테라노스틱 항암제 전구체, 이의 제조방법 및 이의 용도

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20201021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220114

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221101

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230530